[
  {
    "ts": "2026-01-23T06:30:00+00:00",
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
      "content": {
        "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
        "contentType": "STORY",
        "title": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
        "description": "",
        "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
        "pubDate": "2026-01-23T06:30:00Z",
        "displayTime": "2026-01-23T06:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ff057859-25cc-38ab-bf6d-78ba37dc9314/abbvie-dodged-a-patent.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6BytADf.wdgQOFbGSuj0IA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiR.2Irm6EXEA73p_uJuJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T10:30:00+00:00",
    "headline": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
    "summary": "This biotech has candidates in late-stage clinical development.",
    "url": "https://www.fool.com/investing/2026/01/23/lilly-soared-in-2025-but-heres-another-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6899c60a-28ea-325c-8c0d-4fefc86e96ce",
      "content": {
        "id": "6899c60a-28ea-325c-8c0d-4fefc86e96ce",
        "contentType": "STORY",
        "title": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
        "description": "",
        "summary": "This biotech has candidates in late-stage clinical development.",
        "pubDate": "2026-01-23T10:30:00Z",
        "displayTime": "2026-01-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e675b3d8cb6f5cdaf9f793d9878150eb",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Four investors look at something on a computer.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kDI44SVUCI_Nk6dMfOhyGQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e675b3d8cb6f5cdaf9f793d9878150eb.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RDwdWn3hwCTUKhIs16uN3Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e675b3d8cb6f5cdaf9f793d9878150eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/lilly-soared-in-2025-but-heres-another-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-soared-39-2025-103000601.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T14:05:26+00:00",
    "headline": "Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",
    "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",
    "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "61005fb7-fee2-3624-b70b-b2dba818f6b9",
      "content": {
        "id": "61005fb7-fee2-3624-b70b-b2dba818f6b9",
        "contentType": "STORY",
        "title": "Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",
        "description": "",
        "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",
        "pubDate": "2026-01-23T14:05:26Z",
        "displayTime": "2026-01-23T14:05:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/106eebc1d4c6106014e7e7be029085fd",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lmdn2ChsZZWxw2pZZm_unA--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/106eebc1d4c6106014e7e7be029085fd.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GEkH7Pta2oCydPaYw_QgZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/106eebc1d4c6106014e7e7be029085fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T15:20:34+00:00",
    "headline": "Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",
    "summary": "This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.",
    "url": "https://www.fool.com/coverage/filings/2026/01/23/outfront-media-surges-40-in-one-year-then-gets-cut-loose-despite-usd0-30-dividend/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "3187d224-69cf-3a0e-b300-67aa2a71f091",
      "content": {
        "id": "3187d224-69cf-3a0e-b300-67aa2a71f091",
        "contentType": "STORY",
        "title": "Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",
        "description": "",
        "summary": "This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.",
        "pubDate": "2026-01-23T15:20:34Z",
        "displayTime": "2026-01-23T15:20:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/af7ec8d325cf2a320c12c354cd741265",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vnbG7RKzagtuC1AtZnqLKA--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/af7ec8d325cf2a320c12c354cd741265.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tpTWjRWaxFsNazxAotRGEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/af7ec8d325cf2a320c12c354cd741265.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/01/23/outfront-media-surges-40-in-one-year-then-gets-cut-loose-despite-usd0-30-dividend/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/outfront-media-surges-40-one-152034785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OUT"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UAN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]